Arteriolar hyalinosis (AH) in kidney biopsy specimens is a common lesion associated with increased age, hypertension, diabetes, hyperuricaemia, progressive renal disease, and previous calcineurin inhibitor (CNI) use. [1] [2] [3] [4] [5] [6] [7] The association between AH and CNI has been reported in multiple studies, with AH regarded as the most characteristic lesion of CNI nephrotoxicity. 5, 6 Previous studies have demonstrated that chronic CNI nephrotoxicity leads to graft failure. 8 The severity of AH is graded in 1 of 2 ways using the Banff scoring system (ah score and aah score) to distinguish CNI-induced AH lesions from other causes. 9, 10 As CNI exposure increases, the likelihood of AH in transplanted kidneys increases.
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Therefore, an absence of CNI-induced AH lesions could indicate inadequate drug exposure and non-adherence to treatment. 14, 15 AH seen at post-reperfusion biopsy represents an additional risk factor for the development of ischemic injury to the kidney allograft. 16 Most studies focus on CNI exposure when evaluating AH lesions after kidney transplantation. However, the impact of diabetes on AH after kidney transplantation has not been fully elucidated. The aim of this study was to assess the impact of diabetic nephropathy (DN) as a leading cause of AH in patients receiving kidney transplantation.
MATERIALS AND METHODS

Patients and study design
Clinical and pathological data were obtained from 83 patients who underwent living-donor kidney transplantation at Chiba East Hospital from April 2005 to June 2015. Insufficient biopsy specimens, defined as having less than seven glomeruli or the absence of arteries, were excluded. All allograft biopsies were scored according to the Banff classification, and the relationship between the individual histological lesions and clinical data was evaluated. This study protocol was approved by the Ethics Committee of ChibaEast Hospital in March 2017, and study procedures adhered to the Declaration of Helsinki.
Assessment of clinical data and definitions
Baseline clinical data at the time of kidney transplantation was obtained from each patient's medical records. Data on the donor's age, baseline arteriosclerosis (AS) and AH status (using ah scoring) at the 1 h biopsy, and recipient characteristics at the time of kidney transplantation, including age, sex, dialysis requirement before kidney transplantation, and ABO status were included. Uric acid levels, hemoglobin A1c (HbA1c), as well as the presence of hypertension and dyslipidaemia were assessed 1 year after kidney transplantation. The patient's CNI regimen (cyclosporine [CsA] or tacrolimus [Tac] ) and CNI trough levels were assessed at the one-year biopsy. Outcomes measured included both graft and patient survival data. Additionally, we assessed pathological findings of transplanted kidneys obtained from patients who had simultaneous pancreas-kidney transplantation (SPK) from brain-dead donors.
Kidney allograft evaluation by pathological analysis of biopsy specimens
Tissue from kidney allografts was harvested by needle biopsy and evaluated by light microscopy, immunofluorescence, and electron microscopy. Sections of tissue for light microscopy were stained with haematoxylin and eosin, periodic acid-Schiff, periodic acid methenamine silver stain, and Masson trichrome stain. An experienced nephrologist and renal pathologist scored all pathological specimens. Biopsies containing more than seven glomeruli and one artery were deemed adequate. The severity of the pathological findings was scored according to the Banff criteria 2015. 10 Banff ah scores were as follows: No PAS-positive hyaline arteriolar thickening (ah0); mild to moderate PAS-positive hyaline thickening in at least one arteriole (ah1); moderate to severe PAS-positive hyaline thickening in more than one arteriole (ah2); and severe PAS-positive hyaline thickening in many arterioles (ah3). Banff aah scores were as follows: no typical lesions of calcineurin inhibitor-related arteriolopathy (aah0); replacement of degenerated smooth muscle cells by hyaline deposits in only one arteriole, without circumferential involvement (aah1); replacement of degenerated smooth muscle cells by hyaline deposits in more than one arteriole, without circumferential involvement (aah2); and replacement of degenerated smooth muscle cells by hyaline deposits with circumferential involvement, independently of the number of arterioles involved (aah3). Interstitial fibrosis and tubular atrophy (IFTA) severity was deemed mild (IFTA <25%), moderate (IFTA 25-50%), or severe (IFTA >50%). Acute rejection was diagnosed according to the Banff criteria, and advanced AH was defined as having a Banff score of either ah ≥2 or aah ≥2.
Statistical analyses
Data are reported as percentages or as the mean AE standard deviation (SD). Categorical variables were analyzed with the χ 2 test, while continuous variables were assessed using a ttest or Mann-Whitney U-test. Logistic regression analysis was used to evaluate the association of clinical factors with advanced AH. A two-tailed P < 0.05 was considered statistically significant. All statistical analyses were performed using STATA 13.1 software (Stata Corporation, College Station, TX, USA).
RESULTS
Baseline characteristics
The baseline recipient and donor characteristics of the 83 study patients (33 DN and 50 non-DN) are shown in Table 1 . At the time of kidney transplantation, the mean recipient age was 50.7 AE 10.7 (DN) and 49.2 AE 11.8 years (non-DN). The mean donor age was 57.8 AE 10.3 years for DN patients and 57.4 AE 8.9 years for those without DN. The incidence of hypertension was 78.8% in the DN group and 84.0% in the non-DN group. HbA1c (DN: 7.2 AE 1.2%; non-DN: 5.7 AE 0.5%; P < 0.001) and CNI regimen used in the group (CsA/Tac, DN: 27/6; non-DN: 23/27; P = 0.001) were significantly different between both groups. No other parameters were significantly different. The median followup period was 4.5 years. In total, three patients progressed to end-stage renal disease while no patients died if they received a functioning graft.
Incidence of AH in allograft biopsies after transplantation
The prevalence of ah or aah lesions is presented in Figure 1A ,B. The prevalence of both lesions showed a rising trend over time. The scoring distribution of ah ≥ 1, ah ≥ 2, aah ≥ 1, aah ≥ 2 and IFTA in early biopsies (3-12 months after kidney transplantation) and late biopsies (>3 years after kidney transplantation) are shown in Table 2 . Of these, ah lesions (ah ≥ 1) were seen in 29 out of 73 cases (39.7%) in early biopsy specimens and 26 of 31 cases (83.9%) in late biopsy specimens. In contrast, aah lesions (aah ≥ 1) were seen in 7 of 73 cases (9.6%) and 20 of 31 cases (64.5%), respectively. There was a significant difference in ah ≥ 2 (83.3% vs. 36.8%, P = 0.013) and aah ≥ 2 (66.7% vs. 21.1%, P = 0.011) between DN and non-DN in late but not early biopsy specimens. There was no significant difference in IFTA severity between the two groups at either early or late biopsy. The pathological findings of advanced AH in the DN group is presented in Figure 2 .
Factors associated with advanced AH
We defined advanced AH as ah ≥ 2, aah ≥ 2, or both. In the univariate analysis, recipient age ≥60 (odds ratio [OR] = 0.21, 95% confidence interval [CI] = 0.04-0.97, P = 0.045), greater than 3 years after transplantation (OR = 9.20, 95% CI = 2.90-21.18, P = 0.001) and primary DN disease (OR = 3.41, 95% CI = 1.22-9.55, P = 0.019) were all significant predictors of ah ≥ 2. On the other hand, hypertension, baseline AS, acute rejection, and CNI trough level were not significantly associated with ah ≥ 2. In the multivariable analysis, greater than 3 years after transplantation (OR = 11.9; 95% CI = 3.16-44.98; P = 0.001) or primary DN disease (OR = 2.55, 95% CI = 1.47-19.54; P = 0.011) were independent significant risk factors of ah ≥ 2 (Table 3) . Furthermore, a similar result was found for aah ≥ 2. We found that greater than 2 years after transplantation (OR = 41.58, 95% CI = 4.31-400.15, P = 0.001) and primary DN disease (OR = 7.55, 95% CI = 1.49-38.33, P = 0.015) were independent risk factors for aah ≥ 2 (Table 4) .
Comparison of advanced AH in DN, non-DN, and SPK patients
Clinical and pathological features of patients who underwent kidney-pancreas transplantation from brain-dead donors are shown in Table 5 . The control of blood glucose level post-procedure was adequate without insulin therapy in all five cases. This finding was counter to the clinical status of patients with DN in which mean HbA1c of DN recipients at the one year biopsy was 7.2% and most DN recipients (76%) were using insulin. The number of ah ≥ 2 and aah ≥ 2 was 2 and 1 in late biopsies of transplanted kidney, respectively. The incidence of advanced AH (ah ≥ 2 and aah ≥ 2) in DN, non-DN, and simultaneous pancreaskidney transplant patients is shown in Figure 3 . A comparison of aah lesions between the groups showed that DN vs. non-DN (ah ≥ 2: 83.3% vs. 52.6%; aah ≥ 2: 66.7% vs. 21.1%), and DN vs. SPK (ah ≥ 2: 83.3% vs. 40%; aah ≥ 2: 66.7% vs. 20%), respectively.
DISCUSSION
Among pathological processes that may arise in transplanted kidneys, AH lesions are closely related to CNI nephrotoxicity in kidney allograft biopsies and have been Data are shown as a percentage or mean AE standard deviation (SD).
Time after transplantation (years) Ratio of ah lesion (%)
Ratio of aah lesion (%) shown to impact graft function. 8, 12, 13 However, the impact of diabetes on AH progression after transplantation has not been fully elucidated. 17, 18 Our data showed that both Banff ah and aah scores were higher in patients with DN (ah ≥ 2: 83.3% vs. 36.8%, P = 0.013; aah ≥ 2: 66.7% vs. 21.1%, P = 0.011). Furthermore, the presence of DN as the predominant pathologic process with associated ESRD was a risk factor for advanced AH lesions (both ah ≥ 2 and aah ≥ 2), as determined by multivariable analysis.
With regards to the ah score, we suspected that inadequate control of blood glucose levels after kidney transplantation in the DN group contributed to the severity of the ah score. To confirm this association, we assessed five cases of patients with DN who received a dual kidney and pancreas transplant from brain-dead donors. The blood glucose levels of all five cases were perfectly controlled. As a result, the ah score was not severely impacted in the SPK group as compared with the DN group (Table 5 and Fig. 3 ). These data indicated that uncontrolled hyperglycaemia contributed to ah lesions. Previous studies have demonstrated that endothelial cell injury develops as a direct result of increased blood glucose concentration, and leads to ah lesion development. 19 The criterion for the aah score was first discussed in 2007 at a conference in Banff, Canada. 9 Currently, the aah score is used to discriminate CNI-specific arteriolar hyaline deposition from non-specific AH. [13] [14] [15] This scoring system was established to improve inter-observer reproducibility of diagnosis. 20 However, aah lesions are not always characteristic of chronic CNI nephrotoxicity. We observed similar lesions in kidney biopsies taken from naive patients with DN. In the present study, aah lesions increased over time post-transplantation, and the aah score of the DN group was significantly greater than that of the non-DN group in biopsies taken at later time points. If no differences exist in the CNI trough level and exposure time to CNI between the two groups, uncontrolled hyperglycaemia can contribute to aah lesions. Furthermore, aah scores in the SPK patient group were not as severe as those in the DN group (Table 5 and Fig. 3 ). Arteriolar hyalinosis is characterized by hyaline deposition in the vascular endothelial wall. Vascular matrix proteins, such as collagen types I and IV, and fibronectin are increased in these AH lesions in both patient and animal studies. 21, 22 Chiasson et al. demonstrated that endothelial cell-transforming growth factor β (TGF-β) receptor activation induced by Tac treatment played a critical role in causing injury and hyaline change in smooth muscle cells. 23 Another study showed that oxidative stress and inflammatory cytokines, such as TGF-β, induced apoptosis in models of DN. 24 These results indicate that high glucose levels and CNI toxicity could enhance the progression of AH lesions. Further investigation is required to elucidate this relationship.
Several limitations of this study should be noted. First, treatment effects and controls were not included, as this was primarily an observational study. Second, few biopsies were taken from pre-transplant patients with DN, as the availability of such samples were limited. Third, the time between biopsies differed among patients. Finally, the follow-up interval after kidney transplantation was insufficient to evaluate outcomes. In conclusion, primary DN was closely associated with increased Banff ah and aah scores in patients following kidney transplantation. We postulate that better controlled hyperglycemia could ameliorate the progression of both ah and aah lesions. Further study is required to confirm whether advanced AH affects long-term kidney graft outcomes.
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